Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
400 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Phase 1 Recruiting
246 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
A Study of TRK-950 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
49 enrolled
eVOLVE-Meso
Phase 3 Recruiting
825 enrolled
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Phase 2/3 Recruiting
690 enrolled
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
131 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Phase 1/2 Recruiting
234 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Phase 1/2 Recruiting
50 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 Recruiting
180 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
2,130 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Phase 2/3 Recruiting
280 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
413 enrolled
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Phase 2 Recruiting
144 enrolled
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
542 enrolled
Trial of INI-4001 in Patients With Advanced Solid Tumours
Phase 1 Recruiting
50 enrolled
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
320 enrolled
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Phase 2 Recruiting
95 enrolled
LIMITLESS
Phase 3 Recruiting
30 enrolled
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/2 Recruiting
336 enrolled
VIRO-25
Phase 2 Recruiting
142 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Phase 2 Recruiting
276 enrolled
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Phase 2/3 Recruiting
135 enrolled
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 Recruiting
40 enrolled
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Phase 2 Recruiting
245 enrolled
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Phase 2 Recruiting
59 enrolled
METAGIO
Recruiting
500 enrolled
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3 Recruiting
510 enrolled
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Phase 1 Recruiting
12 enrolled
A Study of BND-35 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
280 enrolled
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Phase 1 Recruiting
28 enrolled
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
Phase 1/2 Recruiting
43 enrolled